ENLIVEN THERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 8.32 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- ENLIVEN THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 10.03M shares, a 1.55% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 9.88M shares, a 25.41% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 7.88M shares, a 99.40% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 3.95M shares, a 81.76% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 9.41M shares, a 25.67% increase from fiscal 2024.
- ENLIVEN THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 7.49M shares, a 26.68% increase from fiscal 2023.
- ENLIVEN THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 5.91M shares, a 72.68% decline from fiscal 2022.
- ENLIVEN THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 21.63M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 8.32M shares 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 10.03M shares 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 9.41M shares 10-K · filed 2026-03-03 | |||
| 2025-09-30 | 9.59M shares 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 9.58M shares 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | 9.88M shares 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 7.49M shares 10-K · filed 2026-03-03 | |||
| 2024-09-30 | 7.55M shares 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | 7.56M shares 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | 7.88M shares 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | 5.91M shares 10-K · filed 2025-03-13 | |||
| 2023-09-30 | 5.98M shares 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | 5.77M shares 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | 3.95M shares 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | 21.63M shares 10-K · filed 2024-03-14 | |||
| 2022-09-30 | 21.69M shares 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 21.64M shares 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | 21.66M shares 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | 21.83M shares 8-K · filed 2023-06-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |